136 related articles for article (PubMed ID: 17062081)
1. The CX3C-chemokine fractalkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea.
Gangemi S; Cannavò SP; Guarneri F; Merendino RA; Sturniolo GC; Minciullo PL; Di Pasquale G; Valenzise M; Drago F; Rebora A
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1366-7. PubMed ID: 17062081
[No Abstract] [Full Text] [Related]
2. The CX3C chemokine fractalkine (CX3CL1) is detectable in serum of B cell chronic lymphocytic leukemia patients with lymph node involvement.
Morabito F; Merendino RA; Penna G; Cuzzola M; Stelitano C; Callea V; Di Pasquale G; Minciullo PL; Gangemi S
Acta Haematol; 2005; 113(2):152-4. PubMed ID: 15802897
[No Abstract] [Full Text] [Related]
3. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.
Bjerkeli V; Damås JK; Fevang B; Holter JC; Aukrust P; Frøland SS
Rheumatology (Oxford); 2007 Sep; 46(9):1422-7. PubMed ID: 17616549
[TBL] [Abstract][Full Text] [Related]
4. Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression.
Merendino RA; Di Pasquale G; De Luca F; Di Pasquale L; Ferlazzo E; Martino G; Palumbo MC; Morabito F; Gangemi S
Mediators Inflamm; 2004 Jun; 13(3):205-7. PubMed ID: 15223613
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer.
Brueckmann M; Borggrefe M
Gut; 2007 Mar; 56(3):314-6. PubMed ID: 17339240
[TBL] [Abstract][Full Text] [Related]
6. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
Hasegawa M; Sato S; Echigo T; Hamaguchi Y; Yasui M; Takehara K
Ann Rheum Dis; 2005 Jan; 64(1):21-8. PubMed ID: 15608300
[TBL] [Abstract][Full Text] [Related]
7. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis.
Matsunawa M; Isozaki T; Odai T; Yajima N; Takeuchi HT; Negishi M; Ide H; Adachi M; Kasama T
Arthritis Rheum; 2006 Nov; 54(11):3408-16. PubMed ID: 17075825
[TBL] [Abstract][Full Text] [Related]
8. The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury.
Rancan M; Bye N; Otto VI; Trentz O; Kossmann T; Frentzel S; Morganti-Kossmann MC
J Cereb Blood Flow Metab; 2004 Oct; 24(10):1110-8. PubMed ID: 15529011
[TBL] [Abstract][Full Text] [Related]
9. Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus.
Sato E; Iikuni N; Yoshio T; Minota S; Kamatani N; Okamoto H
Ann Rheum Dis; 2006 Sep; 65(9):1257-9. PubMed ID: 16905589
[No Abstract] [Full Text] [Related]
10. The CX3CL1-CX3CR1 system and psoriasis.
Plant D; Young HS; Watson RE; Worthington J; Griffiths CE
Exp Dermatol; 2006 Nov; 15(11):900-3. PubMed ID: 17002687
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the 3' untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression.
Peraire J; Vidal F; Plana M; Domingo P; Coll B; Viladés C; Garcia F; Veloso S; Gatell JM; Broch M
AIDS; 2007 Apr; 21(7):891-3. PubMed ID: 17415055
[No Abstract] [Full Text] [Related]
12. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
Kastenbauer S; Koedel U; Wick M; Kieseier BC; Hartung HP; Pfister HW
J Neuroimmunol; 2003 Apr; 137(1-2):210-7. PubMed ID: 12667665
[TBL] [Abstract][Full Text] [Related]
13. [Adhesional chemokine, fractalkine].
Umehara H
Nihon Rinsho Meneki Gakkai Kaishi; 2000 Apr; 23(2):90-102. PubMed ID: 10863324
[No Abstract] [Full Text] [Related]
14. Fractalkine in the peritoneal fluid of women with endometriosis.
Shimoya K; Zhang Q; Temma-Asano K; Hayashi S; Kimura T; Murata Y
Int J Gynaecol Obstet; 2005 Oct; 91(1):36-41. PubMed ID: 16109418
[TBL] [Abstract][Full Text] [Related]
15. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma.
Matsubara T; Ono T; Yamanoi A; Tachibana M; Nagasue N
J Surg Oncol; 2007 Mar; 95(3):241-9. PubMed ID: 17323338
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine: moving from chemotaxis to neuroprotection.
Ré DB; Przedborski S
Nat Neurosci; 2006 Jul; 9(7):859-61. PubMed ID: 16801915
[No Abstract] [Full Text] [Related]
17. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions.
Schäfer A; Schulz C; Fraccarollo D; Tas P; Leutke M; Eigenthaler M; Seidl S; Heider P; Ertl G; Massberg S; Bauersachs J
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):55-62. PubMed ID: 17082482
[TBL] [Abstract][Full Text] [Related]
18. Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.
Cotter R; Williams C; Ryan L; Erichsen D; Lopez A; Peng H; Zheng J
J Neurovirol; 2002 Dec; 8(6):585-98. PubMed ID: 12476352
[TBL] [Abstract][Full Text] [Related]
19. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells.
Durkan AM; Alexander RT; Liu GY; Rui M; Femia G; Robinson LA
J Am Soc Nephrol; 2007 Jan; 18(1):74-83. PubMed ID: 17151328
[TBL] [Abstract][Full Text] [Related]
20. Single CX3CL1-Ig DNA administration enhances T cell priming in vivo.
Iga M; Boissonnas A; Mahé B; Bonduelle O; Combadière C; Combadière B
Vaccine; 2007 Jun; 25(23):4554-63. PubMed ID: 17493713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
